REN and prostate cancer: Similarly, there were no shared genetic alterations between colorectal cancer and anti-inflammatory and antirheumatic products, nonsteroids (RG = 0.046, SE = 0.068, P = 0.498), or prostate cancer and agents acting on the renin-angiotensin system (RG = 0.018, SE = 0.031, P = 0.552) and vasodilators used in cardiac diseases (RG = –0.008, SE = 0.064, P = 0.899).